

Research Article

The Effect of Internal Limiting Membrane Cleaning on Epiretinal Membrane Formation after Vitrectomy for Proliferative Diabetic Retinopathy

Alexander Mehta^a, Romeela Rana-Rahman^b, Ingeborg Klaassen^c, Jon Rees^d, David H Steel^{a,b}

^a Newcastle University, Newcastle-upon-Tyne, UK

^b Department of Ophthalmology, Sunderland Eye Infirmary, Sunderland, UK

^c Ocular Angiogenesis Group, Amsterdam UMC, Amsterdam, The Netherlands

^d Faculty of Health Sciences and Well Being, University of Sunderland, Sunderland, UK

Short Title: Internal Limiting Membrane Cleaning after Diabetic Vitrectomy

Corresponding Author:

Professor David Steel,

Department of Ophthalmology

Sunderland Eye Infirmary

Queen Alexandra Road

Sunderland, SR2 9HP, UK

Tel: +44191 565 6256

E-mail: david.steel@ncl.ac.uk

Number of Tables: 4

Number of Figures: 2

Word count: 4207

Keywords:

Internal limiting membrane, Epiretinal membrane, Diabetic vitrectomy, Proliferative diabetic retinopathy, Vitreous proteomics

1 **Abstract**

2 **Purpose**

3 We hypothesised that cleaning the internal limiting membrane (ILM) with a flexible nitinol loop
4 following diabetic vitrectomy without peeling may reduce the common occurrence of postoperative
5 epiretinal membrane (ERM) formation.

6 **Methods**

7 Consecutive patients undergoing vitrectomy for proliferative diabetic retinopathy by one surgeon
8 from 2015-2019 were studied and divided into two cohorts: the control group underwent standard
9 surgery; the ILM-Clean group underwent additional cleaning of the macular retina using a flexible
10 nitinol loop post-vitrectomy. Masked comparison of ERM on optical coherence tomography was
11 performed at 3 months and visual acuity (VA) was measured until 12 months postoperatively.

12 **Results**

13 Baseline demographics, clinical features and protein levels were similar between cohorts. The ILM-
14 Clean group (n=56) had fewer clinically significant ERM compared to the control group (n=50)
15 (4%vs.20%;p=0.01) and a significantly lower proportion of the ILM-Clean group required revision
16 surgery (2%vs.14%;p=0.02). VA in the ILM-Clean group was significantly better than the control group
17 at 3 months (0.35vs.0.50logMAR;p=0.02) but not at 12 months (0.34vs.0.43logMAR;p=0.17).

18 **Conclusion**

19 ILM cleaning with a flexible nitinol loop following diabetic vitrectomy resulted in significant reduction
20 in ERM formation and reduced necessity for revision surgery. There was significant improvement in
21 VA at 3 months but not over longer follow-up.

22 **Introduction**

23 Epiretinal membrane (ERM) formation is a well-known association of proliferative diabetic
24 retinopathy (PDR) and can lead to a variety of tractional consequences with reduced vision. Its
25 occurrence relates to a range of effects secondary to raised glucose levels including changes in
26 vitreous structure, an abnormal adhesion between the vitreous cortex and internal limiting
27 membrane (ILM) of the retina, and a pro-proliferative cytokine mix in the vitreous cavity [1,2].
28 Vitrectomy surgery is a proven and successful treatment for the complications of PDR where the
29 surgical aims of treatment include removing vitreous haemorrhage and relieving vitreoretinal
30 traction [3]. However, ERM is observed postoperatively after diabetic vitrectomy in 20–50% of cases,
31 is associated with macular thickening, can affect visual outcome and has been reported to require
32 revision surgery in 7–22% of cases [4–8]. The exact cause of this is uncertain although surgical and
33 proteomic risk factors have been described [9,10]. ILM peeling has been proposed as an effective
34 strategy to reduce the occurrence of significant ERM after surgery [11,12] but its use has been
35 questioned because of its potential to cause harm [13]. We carried out a prospective study to assess
36 the effect of ILM cleaning, without ILM peeling, using a flexible nitinol loop on the occurrence of ERM
37 after surgery for PDR. Vitreous proteomic assays were carried out on a range of relevant proteins in
38 all cases and peeled ILM was examined by transmission electron microscopy after ILM cleaning in a
39 subset of cases.

40 **Materials and Methods**

41 Data from consecutive patients undergoing vitrectomy for PDR by one surgeon over a 42-month
42 period from 2015 to 2019 was retrospectively analysed. The cohort was divided into two cohorts
43 within recruitment occurring in both cohorts over 21 months. In the first cohort, which in henceforth
44 referred to as the control cohort, the ILM was not cleaned, and in the second cohort it was cleaned
45 with a Finesse flex loop (Alcon Grieshaber, Schaffhausen, Switzerland), otherwise surgery was
46 identical.

47 Indications for surgery included vitreous haemorrhage, tractional retinal detachment with and
48 without a rhegmatogenous component. Patients were excluded if there had been previous
49 vitrectomy, there was a prior history of diabetic macular oedema (DMO) requiring treatment with
50 retinal photocoagulation or intravitreal therapies within the preceding 2 years, silicone oil

51 tamponade was required, there was less than 3 months follow up or postoperative spectral domain
52 optical coherence tomography (SDOCT) was not performed 3–4 months postoperatively.

53 All surgeries were carried out using the Alcon Constellation 25g Ultravit system (Alcon, Fort Worth,
54 Texas, USA) with wide angle viewing using a standardised technique. After core vitrectomy,
55 delamination and removal of all posterior hyaloid face and fibrovascular membranes was carried out.
56 This was done primarily with the vitreous cutter alone, and intravitreal scissors were used only if
57 necessary, as previously described [14,15]. Careful inspection to detect the presence of vitreoschisis
58 was carried out and staining of residual vitreous gel using diluted triamcinolone (TMC) was used in all
59 cases. Any vitreous remnants and epiretinal membrane detected was peeled using the vitreous
60 cutter and forceps as necessary.

61 In a second cohort of patients, after staining with TMC, and after peeling of membranes as above, a
62 Finesse flex loop was used to gently brush the retina, to remove any residual epiretinal tissue
63 present, concentrating on the macula area within the vascular arcades. Particular care was taken to
64 brush all areas extending for a disc diameter in radius around the foveal centre in a systematic way
65 using radial and concentric brush directions, dictated by surgical ease. The procedure was performed
66 regardless of the presence of discernible vitreous remnants identified by TMC, however the presence
67 of patches of discernible vitreous remnants with strands or sheets of membrane after TMC
68 application was recorded (see supplementary video).

69 Endolaser retinal photocoagulation was carried out to complete any deficiencies in previous laser.
70 Retinal breaks were treated with argon laser retinopexy. Sulphur hexafluoride gas or air were used as
71 postoperative tamponade where needed. Preoperative anti-VEGF therapy was used in selected
72 patients relating to the activity and extent of the neovascularization. Combined phacovitrectomy was
73 carried out in cases with visually significant cataract obscuring the operative view.

74 The primary outcome was the presence and severity of ERM on SDOCT at 3–4 months
75 postoperatively. Patients underwent SDOCT (30 by 30° horizontal grid protocol with 60-micron line
76 spacing) using a Spectralis HRA®+ SDOCT (Heidelberg Engineering, Heidelberg, Germany). The
77 SDOCTs were graded by two independent observers masked to the intervention group for the
78 presence of ERM, which was defined as a hyper-reflective inner retinal band. The presence of any
79 foveal (within central 1mm²) and eccentric (outside central 1mm² but within a standard 6mm Early
80 Treatment Diabetic Retinopathy Study (ETDRS) circle) ERM was recorded and graded as absent (score
81 0), present (score 1), or present and associated with retinal plication and/or peg-like attachments
82 (score 2) (as shown in Fig. 1) and making a total maximum score of 4, as reported previously [16].
83 Central macular thickness (CMT: average retinal thickness over the central 1mm diameter subfield,

84 and macular volume were recorded, as was the presence of intraretinal cysts. ERM was designated as
85 clinically significant if the following criteria were met: 1) ERM involving the foveal centre associated
86 with a change in foveal architecture and plication. 2) Eccentric ERM if associated with retinal
87 plication and in continuity with an area of central retinal thickening.

88 A variety of pre-, intra- and postoperative characteristics of the patients were recorded, including
89 age, gender, type and duration of diabetes and glycosylated haemoglobin (HbA1c) level at the time
90 of vitrectomy. The amount of preoperative panretinal photocoagulation (PRP) was graded as equal
91 to, or more than, ETDRS full scatter, less than standard ETDRS full scatter or no preoperative PRP
92 [17]. The extent of any retinal haemorrhage was recorded as more, less or the same as the standard
93 2a photograph used in the ETDRS study and the presence of any preretinal haemorrhage recorded
94 [18] and graded as absent, extramacular or premacular. The extent of the vitreoretinal adhesion
95 areas was estimated based on disc areas. The position of neovascularisation was recorded as none,
96 disc attachment only, posterior pole attachment only or 1–4 quadrants of anterior vitreoretinal
97 attachment. Tractional retinal detachment was recorded as absent, eccentric to macular or macular
98 involving. The number of applications of intraoperative laser was recorded. Patients were followed
99 up at approximately 3, 6 and 12 months postoperatively as per routine care. The number, timing and
100 indications for repeat surgery were recorded. Best corrected visual acuity (BCVA) using an ETDRS
101 letter chart was recorded at baseline and 3, 6 and 12 months postoperatively, and converted to
102 logMAR for analysis. LogMAR values corresponding to count fingers (CF), hand movements (HM),
103 perception of light (PL) were substituted with 1.98, 2.28 and 2.70 respectively.

104 **Proteomics**

105 In all patients, a sample of undiluted vitreous (0.5–1.0ml) was aspirated with high cut rate into a 2ml
106 syringe prior to initiation of full vitrectomy, and then frozen at -80°C. A range of cytokines [10,19]
107 and growth factors based on previous work (namely vascular endothelial growth factor (VEGF) A,
108 placental growth factor, connective tissue growth factor, monocyte chemoattractant protein 1 (MCP-
109 1), interleukin 6 (IL-6), interleukin 8 (IL-8), angiotensin 2, intercellular adhesion molecule 1, matrix
110 metalloproteinase 2, matrix metalloproteinase 9, tissue necrosis factor α) were quantified by using a

111 customisable array-based multiplex immunoassay (Human Quantibody array, RayBiotech, Norcross,
112 GA, USA) as previously described [19].

113 **Electron Microscopy**

114 After completion of recruitment to the main cohort, in four separate patients undergoing vitrectomy
115 for PDR, and after ILM cleaning with the Finesse flex loop as per our protocol described above, the
116 ILM was peeled and then retrieved for transmission electron microscopy.

117 Samples were fixed in 2% glutaraldehyde in 0.1M sodium cacodylate buffer and processed as
118 previously described [20]. Detailed examination of the tissue was performed to determine the
119 occurrence of any cellular debris on the vitreous surface of the ILM, and any detectable evidence of
120 loop related surface marks such as grooving, or ILM disruption. The extent of any vitreous side
121 epiretinal membrane was graded in extent as previously described [20].

122 Informed consent for the collection of the vitreous and ILM specimens was obtained from the
123 subjects after explanation of the nature of the study. These were carried out in accordance with the
124 ethical standards of an institutional research committee (National Health Service South East Coast–
125 Surrey Research Ethics Committee – reference 12/LO/0130) and with the 1964 Declaration of
126 Helsinki and its later amendments. Use of the retrospectively collected clinical data was classed as
127 service evaluation under UK guidelines and as such did not require separate ethical review.

128 **Statistical analysis**

129 Descriptive and statistical analysis was performed using SPSS version 25. Patients demographic
130 characteristics, pre- and post-operative variables are presented in terms of mean, standard deviation
131 and range, median, interquartile range or percentage as appropriate. Two-sample unpaired t-tests
132 were used to compare continuous variables or the Mann-Whitney test as appropriate. Associations
133 between non-continuous variables were analysed using the chi-square test and Fisher's exact
134 probability. Analysis of covariance was used to compare the improvement in vision postoperatively
135 at 3-months between the two groups taking into account the preoperative vision as a covariate.
136 Logistic regression was performed to assess factors associated with an ERM score of ≥ 1
137 postoperatively at 3 months using the forward method with a significant reduction in log likelihood

138 being used to retain factors in the model. Statistical significance was considered with a p-value of
139 0.05 or less.

140 **Results**

141 During the study period 157 primary vitrectomies for the complication of PDR were carried out.
142 Silicone oil was used in 7 cases, SDOCT were unavailable for 13 eyes (9 in the control group and 4 in
143 the ILM clean group), 21 cases had a prior history of treatment of DMO and 10 eyes were fellow
144 eyes. 106 eyes of 106 patients were thus studied, with 50 in the control group and 56 in the ILM
145 clean group. The mean age was 52 years (standard deviation 15, range 22 to 82) and 55 (52%) were
146 male. The groups were well matched by their clinical features at baseline and as observed during
147 surgery (Table 1) and vitreous protein levels (Table 2). All but two patients were white British in
148 ethnicity. Follow up was completed in 44/50 (88%) and 38/50 (76%) of the control group and 49/56
149 (86%) and 44/56 (79%) in the ILM clean group at 6 and 12 months respectively.

150 In the ILM clean group there were patches of discernible vitreous remnants present as manifest by
151 TMC staining during surgery in 17 of the 56 (30%) eyes. During the ILM cleaning, an unintentional ILM
152 tear was created in 2 eyes, both at approximately 1500 microns from the foveal centre. In these
153 cases, the torn ILM was locally removed only without peeling the ILM at the fovea.

154 The kappa coefficient for interrater reliability in grading ERM presence on SDOCT was 0.80 (95%
155 confidence intervals: 0.66-0.94). There was a significant reduction in the severity of the foveal,
156 extrafoveal and clinically significant ERM between the ILM clean and control groups. Similarly, the
157 mean CMT and macular volume was reduced in the ILM clean group. There was a significant
158 difference in postoperative visual acuity (VA) between the two groups at 3 months (mean logMAR
159 0.35 vs. 0.50, $p=0.02$) (Table 3). When the preoperative VA was included as a covariate the significant
160 difference in postoperative vision persisted ($p=0.008$). The significant difference in postoperative VA
161 persisted at 6 months (mean logMAR 0.33 (SD 0.27) vs. 0.46 (SD 0.40), $p=0.05$) but was non-
162 significant at 12 months (mean logMAR 0.34 (SD 0.29) vs. 0.43 (SD 0.38), $p=0.17$).

163 There was a reduction in ERM in both patients with vitreous haemorrhage and macular tractional
164 retinal detachment, but the effect was only significant in the vitreous haemorrhage group. There was
165 no reduction in the occurrence of ERM in the 5 patients with combined tractional rhegmatogenous
166 retinal detachment (CTRD) who all had ERM postoperatively (Table 4).

167 By the end of 12 months, follow up revision surgery had been required in 7 of the control patients – 5
168 for tractional ERM and 2 for postoperative vitreous cavity haemorrhage (POVCH). In the ILM clean
169 cohort revision vitrectomy had been required in 1 for POVCH ($p=0.02$). In the control group, 3

170 patients were treated with postoperative anti-VEGFs and 3 Iluvien® for DMO. In the ILM clean group,
171 3 patients had postoperative anti-VEGFs and 1 Iluvien® for DMO. In both groups, 8 patients
172 underwent cataract surgery in the first 12 months following initial vitrectomy (p=0.806).

173 **Prediction of ERM by baseline features**

174 Using the overall study population (n=106), 64 (60%) of these patients had at least some ERM
175 identified either eccentrically or foveally (defined as a total score of 1 or more out of a maximum of
176 4) in the initial 3 months. The features identified by logistic regression as being predictive of ERM
177 with a score ≥ 1 was the control group vs. ILM clean group (odds ratio 3.652 (1.476–9.036), p=0.005),
178 number of intraoperative laser applications (odds ratio 0.999 (0.998–1.000), p=0.019) and the
179 indication of vitrectomy being a CTRD (odds ratio 3.552 (1.208-10.440), p=0.021).

180 **Transmission electron microscopy**

181 In the ILM specimens examined by electron microscopy after ILM cleaning, the ILM surface was
182 generally devoid of vitreous side epiretinal membrane, but occasional foci of cells and collagen were
183 seen. We found no signs of ILM disruption but did find occasional and rare areas of focal thinning
184 which may have been related to the ILM cleaning (as per Fig. 2).

185 **Discussion**

186 We found a significant reduction in ERM 3 months after vitrectomy for the complications of PDR in
187 the patients who underwent ILM cleaning using the Finesse flex loop. The groups were well matched
188 both by clinical features and vitreous protein levels. The reduction in ERM was associated with a
189 reduction in retinal thickness compared to the comparator cohort without ILM cleaning, with a
190 concomitant significant improvement in VA at 3 months. This difference was non-significant by 12
191 months but there was a significant reduction in the requirement for revision vitrectomy in the ILM
192 cleaning group.

193 The use of TMC to detect residual vitreous attachment in vitrectomy for PDR has been described
194 previously [21–23], but we are not aware of a study systematically examining the effect of ILM
195 cleaning with a membrane scraping device in patients with PDR. Vitreoschisis and residual vitreous
196 adhesion to the ILM surface are well known features of PDR and its associated vitreopathy [1,24–26].
197 Removal of this material can improve surgical results by reducing rebleeding and recurrent traction,
198 and the particulate staining achieved by dilute TMC can aid in its identification. It can however be
199 difficult to peel conventionally being tenuous with a tendency to shred with forceps. We chose to use
200 the Alcon Grieshaber Finesse flex loop. This is a flexible nitinol loop that in its fully extended position
201 is less rigid than the more established diamond dusted membrane scraper (DDMS). The flex loop has

202 a series of fine 15micron high tines which can be used to remove the remaining layer of posterior
203 cortical vitreous. The tines are triangular shaped and approximately half the height of diamonds on a
204 DDMS. Similarly, the loop has approximately half the rigidity of a DDMS reducing the chances of ILM
205 trauma, abrasion and unintentional tearing, which only occurred in 2 cases. Interestingly examination
206 of the 4 ILM specimens we studied after ILM peeling showed very few signs of inner surface trauma
207 or scratches, as has been observed with the DDMS [27,28]. Other authors have used alternative
208 instruments to remove vitreous remnants including polyvinyl alcohol sponges in the case of
209 rhegmatogenous retinal detachments, which the authors referred to as vitreous wiping [29]. It is
210 likely both instruments have the same effect. We cleaned the ILM in a systematic way even when
211 there was no discernible adherent vitreous on the fovea as an adherent layer of epiretinal tissue has
212 been shown to be highly prevalent in diabetic eyes with advanced retinopathy [30]. We found that in
213 30% of eyes there were macroscopic patches of vitreous remnants identified by TMC at the fovea.

214 The presence of ERM after surgery for PDR has been widely reported with its prevalence ranging
215 from 20–53% [31–33] relating to case mix and the methods of detection. We found that over 70% of
216 our initial control group had some evidence of ERM on SDOCT at 3 months after surgery, although
217 this was only thought to be of clinical significance in 20%. Revision surgery was carried out in 5 (10%)
218 of these cases, although it has been reported to be a common cause for revision surgery with or
219 without associated retinal detachment [8] in some series. Risk factors for the occurrence of
220 significant ERM after surgery have been reported as including the activity of the retinopathy, the
221 extent of fibrovascular proliferation, the occurrence of postoperative vitreous cavity haemorrhage
222 and residual fibrovascular stumps after surgery [9]. It has been noted that IL-6, IL-8 and MCP-1 are
223 upregulated in vitreous samples with ERM recurrence undergoing revision surgery relative to the
224 original surgery [10]. It has been postulated that its occurrence is related to the pathology of diabetic
225 vitreopathy with residual epiretinal tissue acting as both a source and scaffold for recurrent ERM,
226 with inflammatory and pro fibrotic mediators associated with both the PDR and the surgery itself
227 stimulating proliferation and contracture of epiretinal remnants [9]. Pre-existing and surgically
228 induced retinal holes may also contribute to the process by adding to the complexity of dissection
229 and leaving residual epiretinal membranes, tissue trauma from hole creation and laser, and retinal
230 pigment epithelium cell migration. In keeping with this, we found that the amount of intraoperative
231 laser applications and the presence of a CTRD were predictive for the risk of clinically significant ERM
232 occurring after surgery. Indeed, of the 5 eyes with CTRDs included in the total cohort, 4 developed
233 clinically relevant ERMs after surgery, including one in the ILM clean group, although this case did not
234 undergo revision surgery as it was felt to be too mild to warrant repeat intervention. We measured
235 the levels of several vitreous proteins, which have previously been found to be abnormal in eyes with

236 PDR in previous studies at the time of vitrectomy surgery [19]. We did not find any of the proteins
237 were predictive of postoperative ERM. Importantly however there was no significant difference in
238 the levels between the two cohorts reinforcing their matching.

239 Other authors have proposed ILM peeling as a technique to reduce ERM formation in vitrectomy for
240 PDR [11,12] with a reduction in the occurrence of ERM from 38–49% to 0–21%. There have been
241 reports of reduced vision after ILM peeling in advanced diabetic retinopathy perhaps relating to the
242 greater adherence of ILM to its underlying Müller cell endplates with greater resultant trauma in
243 diabetic eyes [13,34,35]. Despite reducing macular thickness, ILM peeling did not improve VA
244 significantly at 3 months in either of the two cited studies and also has not been shown to improve
245 visual results in patients undergoing vitrectomy for diabetic macular oedema [36]. We therefore
246 wished to assess whether ILM cleaning could give comparable results to ILM peeling without the
247 associated risks and perhaps improved vision. ILM cleaning significantly reduced the occurrence and
248 severity of ERM, including clinically significant ERM from 10 (20%) cases to 2 (4%) and no cases
249 required revision surgery for ERM in the ILM clean cohort, compared to 5 in the control group. The
250 central macular thickness was reduced as was the case after ILM peeling, and VA was improved at 3
251 months but not after 12 months when revision surgery had been completed and several patients had
252 undergone treatment for macular oedema. The apparent improvement by 12 months in VA in the
253 control group (3-month mean: 0.50 logMAR; 12-month mean: 0.43 logMAR) compared to the
254 stability of the ILM-Clean group (3-month mean: 0.35 logMAR; 12-month mean: 0.34 logMAR) was
255 due to the increased proportion of control group patients treated with revision surgery (14% vs. 2%),
256 intravitreal medication (12% vs. 7%) or cataract surgery (16% vs. 14%).

257 ILM cleaning did not eliminate all ERM but there were only 4 (7%) cases with ERM involving the
258 central 1mm in the ILM clean group compared to 9 (18%) in the control group. Similarly,
259 Michalewska et al found that 21% of patients that had ILM peeling had ERM outside the area of the
260 ILM peel [12]. We also observed that on the four ILMs examined with TCM after cleaning, there were
261 small remnants of ERM still persistent albeit sparse. It would appear that it is difficult to completely
262 clean the ILM of all epiretinal tissue. It is also worth noting that postoperative ERM is more common
263 in CTRD cases perhaps relating to cellular migration through the retinal breaks. Similarly, the
264 reduction in ERM in cases with macular tractional rhegmatogenous retinal detachments was non-
265 significant perhaps relating to greater Müller cell activation.

266 The study has several limitations. It was not randomised but the groups were well matched for
267 baseline clinical features including vitreous attachment, extent of intraoperative laser and vitreous
268 cytokine levels known to be related to preretinal fibrosis. We did not have preoperative SDOCT scans

269 as the majority of the patients had vitreous haemorrhage at baseline so could not exclude a
270 difference in macular thickening at baseline between the groups. It should be noted however that
271 we excluded patients with known pre-existing maculopathy to reduce this risk. We excluded patients
272 requiring silicone oil insertion and so cannot extrapolate our results to them. We only recorded ERM
273 at one-time point postoperatively and results may have differed at other time points. ERM after
274 vitrectomy has been shown to vary with the time postoperatively [32], but all the patients who
275 required vitrectomy for ERM in the 12 months follow up had clinically significant ERM at the 3-month
276 time point. Late ERM formation significant enough to require vitrectomy would appear to be rare.
277 The population studied was overwhelmingly white Caucasian and results may differ in other racial
278 groups. We did not have details of postoperative glucose control but preoperatively there was no
279 significant difference in glycosylated haemoglobin preoperatively between the groups.

280 **Conclusion**

281 In conclusion, we report a significant reduction in the prevalence of ERM after vitrectomy for PDR by
282 using a technique of ILM cleaning with a flexible nitinol loop. Repeat surgery for tractional
283 maculopathy within 12 months postoperatively was reduced by means of the technique, and there
284 was a significant improvement in postoperative VA at 3 and 6 months postoperatively. Patients with
285 CTRDs had a higher incidence of postoperative ERM which was not prevented by ILM cleaning
286 suggesting that other techniques should be considered in this group of patients in particular. Further
287 evaluation to confirm these results in randomised studies is needed.

288

289 **Statements**

290 **Acknowledgement (optional)**

291 Nil

292 **Statement of Ethics**

293 Informed consent for the collection of the vitreous and ILM specimens was obtained from the
294 subjects after explanation of the nature of the study. These were carried out in accordance with the
295 ethical standards of an institutional research committee (National Health Service South East Coast–
296 Surrey Research Ethics Committee – reference 12/LO/0130) and with the 1964 Declaration of
297 Helsinki and its later amendments. Use of the retrospectively collected clinical data was classed as
298 service evaluation under UK guidelines and as such did not require separate ethical review.

299 **Disclosure Statement**

300 D Steel reports payments for consultancy from Alcon, Roche and Gyroscope as well as grant support
301 from Alcon for projects unrelated to the reported work. The other authors have no conflicts of
302 interest to declare.

303 **Funding Sources**

304 This study was partially funded by Bayer plc (VP01). The grant supported the proteomic analysis.

305 **Author Contributions**

306 A Mehta drafted the initial manuscript and assisted with the data analysis, revised and approved the
307 final version and prepared the manuscript for submission. R Rana-Rahman collected the data and
308 approved the final manuscript. I Klaassen carried out the proteomic analysis and approved the final
309 manuscript. J Rees carried out the data analysis and approved the final manuscript. D Steel conceived
310 the idea, carried out the surgeries, drafted the manuscript and approved the final version.

References [Numerical]

1. Sebag J. Diabetic Vitreopathy (Guest Editorial). *Ophthalmology*. 1996 Feb;103(2):205–6.
2. Costa Ede P, Rodrigues EB, Farah ME, Sebag J, Meyer CH. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy. *Curr Pharm Biotechnol*. 2011 Mar;12(3):410–22.
3. Jackson TL, Johnston RL, Donachie PH, Williamson TH, Sparrow JM, Steel DH. The Royal College of Ophthalmologists' National Ophthalmology Database Study of Vitreoretinal Surgery: Report 6, Diabetic Vitrectomy. *JAMA Ophthalmol*. 2016 Jan;134(1):79–85.
4. Blankenship GW, Machermer R. Long-term Diabetic Vitrectomy Results. Report of 10 year follow-up. *Ophthalmology*. 1985 Apr;92(4):503–6.
5. Schiff WM, Barile GR, Hwang JC, Tseng JJ, Cekic O, Del Priore LV et al. Diabetic vitrectomy: influence of lens status upon anatomic and visual outcomes. *Ophthalmology*. 2007 Mar;114(3):544–50.
6. Oshima Y, Shima C, Wakabayashi T, Kusaka S, Shiraga F, Ohji M et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. *Ophthalmology*. 2009 May;116(5):927–38.
7. Yorston D, Wickham L, Benson S, Bunce S, Sheard R, Charteris D. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. *Br J Ophthalmol*. 2008 Mar;92(3):365–68.
8. Gupta B, Sivaprasad S, Wong R, Laidlaw A, Jackson TL, McHugh D et al. Visual and anatomical outcomes following vitrectomy for complications of diabetic retinopathy: the DRIVE UK study. *Eye*. 2012 Apr;26(4):510–6.
9. Hsu YR, Yang CM, Yeh PT. Clinical and histological features of epiretinal membrane after diabetic vitrectomy. *Graefes Arch Clin Exp Ophthalmol*. 2014 Mar;252(3):401–10.
10. Yoshida S, Kobayashi Y, Nakao S, Sassa Y, Hisatomi T, Ikeda Y et al. Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathy. *Clinical Ophthalmol*. 2017 Sep;11(1):1697–1705.
11. Chang PY, Yang CM, Yang CH, Chen MS, Wang JY. Pars plana vitrectomy for diabetic fibrovascular proliferation with and without internal limiting membrane peeling. *Eye*. 2008 Dec;23(4):960–5.
12. Michalewska Z, Bednarski M, Michalewski J, Jerzy N. The role of ILM peeling in vitreous surgery for proliferative diabetic retinopathy complications. *Ophthalmic Surg Lasers Imaging Retina*. 2013 May;44(3):238–42.
13. Romano MR, Romano V, Vallejo-Garcia JL, Vinciguerra R, Romano M, Cereda M et al. Macular hypotrophy after internal limiting membrane removal for diabetic macular edema. *Retina*. 2014 Jun;34(6):1182–9.
14. Guthrie G, Magill H, Steel DH. 23-gauge versus 25-gauge vitrectomy for proliferative diabetic retinopathy: a comparison of surgical outcomes. *Ophthalmologica*. 2015 Feb;233(2):104–11.
15. Steel DH, Connor A, Habib MS, Owen R. Entry site treatment to prevent late recurrent postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. *Br J Ophthalmol*. 2009 Dec;94(9):1219–25.
16. Wong Y, Steel DHW, Habib MS, Stubbing-Moore A, Bajwa D, Avery PJ et al. Vitreoretinal interface abnormalities in patients treated with ranibizumab for diabetic macular oedema. *Graefes Arch Clin Exp Ophthalmol*. 2017 Apr;255(4):733–42.

17. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. *Ophthalmology*. 1987 Jul;94(7):761–74.
18. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. *Ophthalmology*. 1991 May;98(5 Suppl):786–806.
19. Klaassen I, de Vries EW, Vogels IMC, van Kampen AHC, Bosscha MI, Steel DHW et al. Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes. *PLoS One*. DOI: 10.1371/journal.pone.0187304.
20. Steel DH, Dinah C, Madi HA, White K, Rees J. The staining pattern of brilliant blue G during macular hole surgery: a clinicopathologic study. *Invest Ophthalmol Vis Sci*. 2014 Aug;55(9):5924–31.
21. Matsumoto H, Yamanaka I, Hisatomi T, Enaida H, Ueno A, Hata Y et al. Triamcinolone acetonide-assisted pars plana vitrectomy improves residual posterior vitreous hyaloid removal: ultrastructural analysis of the inner limiting membrane. *Retina*. 2007 Feb;27(2):174–9.
22. Enaida H, Hata Y, Ueno A, Nakamura T, Hisatomi T, Miyazaki M et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. *Retina*. 2003 Dec;23(6):764–70.
23. Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. *Graefes Arch Clin Exp Ophthalmol*. 2002 Jun;240(6):423–9.
24. Sebag J. Vitreoschisis. *Graefes Arch Clin Exp Ophthalmol*. 2008 Mar;246(3):329–32.
25. Chu TG, Lopez PF, Cano MR, Freeman WR, Lean JS, Liggett PE et al. Posterior vitreoschisis: An echographic finding in proliferative diabetic retinopathy. *Ophthalmology*. 1996 Feb;103(2):315–22.
26. Schwartz SD, Alexander R, Hiscott P, Gregor ZJ. Recognition of vitreoschisis in proliferative diabetic retinopathy: A useful landmark in vitrectomy for diabetic traction retinal detachment. *Ophthalmology*. 1996 Feb;103(2):323–8.
27. Hirakata A, Inoue M, Oshitari K, Okada AA, Nagamoto T, Tano Y. Histopathological examination of internal limiting membrane surface after scraping with diamond-dusted membrane scraper. *Acta Ophthalmol*. 2010 Nov;88(7):e293–4.
28. Mahajan VB, Chin EK, Tarantola RM, Almeida DR, Somani R, Boldt HC et al. Macular Hole Closure With Internal Limiting Membrane Abrasion Technique. *JAMA Ophthalmol*. 2015 Jun;133(6):635–41.
29. van Overdam KA, van Etten PG, van Meurs JC, Manning SS. Vitreous Wiping, a new technique for removal of vitreous cortex remnants during vitrectomy. *Acta Ophthalmol*. 2019 Aug;97(5):e747–e752.
30. Gandorfer A, Rohleder M, Kampik A. Epiretinal pathology of vitreomacular traction syndrome. *Br J Ophthalmol*. 2002 Aug;86(8):902–9.
31. Messmer E, Bornfeld N, Oehlschläger, Heinrich T, Foerster MH, Wessing A. Epiretinal membrane formation after pars plana vitrectomy in proliferative diabetic retinopathy. *Klin Monbl Augenheilkd*. 1992 Apr;200(4):267–72.
32. Im JC, Kim JH, Park DH, Shin JP. Structural Changes of the Macula on Optical Coherence Tomography after Vitrectomy for Proliferative Diabetic Retinopathy. *Ophthalmologica*. 2017 Oct;238(4):186–95.

33. Yang CM, Yeh PT, Cheng SF, Yang CH, Chen MS. Macular appearance after diabetic vitrectomy for fibrovascular proliferation: an optical coherence tomography study. *Acta Ophthalmol.* 2010 Mar;88(2):193–8.
34. Kumagai K, Hangai M, Ogino N, Larson E. Effect of internal limiting membrane peeling on long-term visual outcomes for diabetic macular edema. *Retina.* 2015 Jul;35(7):1422–8.
35. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. *Retina.* 2007 Jun;27(5):557–66.
36. Rinaldi M, dell'Omo R, Morescalchi F, Semeraro F, Gambicorti E, Cacciatore F et al. ILM peeling in nontractional diabetic macular edema: review and metanalysis. *Int Ophthalmol.* 2018 Dec;38(6):2709–14.

Figure Legends

Fig. 1. Grading of ERM on SDOCTs at 3 months postoperatively. Panel 'a' illustrates an ERM with plication and involvement of the central fovea. Panel 'b' shows a linear ERM with foveal involvement. Note in this image an ETDRS grid has been overlaid on the infrared image to allow accurate detection of the extent of the ERM. Panel 'c' shows an eye with no discernible ERM.

Fig. 2. Transmission electron microscopy images of peeled ILM after ILM cleaning. Panel 'a' shows a segment of ILM with clean and smooth vitreous side of the ILM and irregular retinal side. Panel 'b' is a higher power view of 'a'. There were infrequent areas of ILM with focal irregularities in the vitreous side (arrows) (Panel 'c'). There were also occasional areas of cellular remnants (arrow) (Panel 'd').